ABSTRACT
Intrathecal administration of anti-infectives is indicated in central nervous system infections by multiresistant pathogens when drugs that can reach adequate cerebrospinal fluid (CSF) concentrations by systemic therapy are not available. Antibiotics that readily pass the blood-brain and blood-CSF barriers and/or that have low toxicity allowing an increase in the daily dosage should not be used for intrathecal therapy. Intrathecal therapy is accompanied by systemic treatment. Antibacterials indispensable for intrathecal therapy include aminoglycosides, colistin, daptomycin, tigecycline, and vancomycin. Limited experience suggests the utility of the antifungals amphotericin B and caspofungin. Intraventricular administration ensures distribution throughout the CSF compartment, whereas intralumbar dosing often fails to attain adequate antibiotic concentrations in the ventricles. The individual dose is determined by the estimated size of the CSF space and by the estimated clearance from CSF. For moderately lipophilic anti-infectives with a molecular weight above approximately 1,000 g/mol, as well as for hydrophilic drugs with a molecular weight above approximately 400 g/mol, one daily dose is normally adequate. The ventricular drain should be clamped for 15 to 120 min to facilitate the distribution of the anti-infective in the CSF space. Therapeutic drug monitoring of the trough levels is necessary only in cases of therapeutic failure.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use , Central Nervous System Bacterial Infections/drug therapy , Central Nervous System Fungal Infections/drug therapy , Anti-Bacterial Agents/cerebrospinal fluid , Antifungal Agents/cerebrospinal fluid , Humans , Injections, SpinalABSTRACT
Aspergillosis is a rare fungal infection in newborns, and its morbidity and mortality are high. Voriconazole (VRCZ) is the first-line antifungal agent for invasive Aspergillus infection, but little data is available about its pharmacokinetics in infants. We report a case of a premature infant who developed ventriculitis due to Aspergillus fumigatus and received combination antifungal therapy including VRCZ. ß-D glucan and Aspergillus antigen index were elevated in the cerebrospinal fluid (CSF). We titrated the dose of VRCZ by monitoring plasma and CSF concentrations. The CSF to plasma concentration ratio of VRCZ ranged from 0.47 to 1.36 (median 0.71). While VRCZ adequately penetrates the blood-brain barrier, its concentration is highly variable in infants.
Subject(s)
Antifungal Agents , Aspergillus fumigatus , Cerebral Ventriculitis/drug therapy , Neuroaspergillosis/drug therapy , Voriconazole , Antifungal Agents/blood , Antifungal Agents/cerebrospinal fluid , Antifungal Agents/therapeutic use , Drug Monitoring , Humans , Infant, Newborn , Male , Voriconazole/blood , Voriconazole/cerebrospinal fluid , Voriconazole/therapeutic useABSTRACT
Robust population pharmacokinetic (PK) data for fluconazole are scarce. The variability of fluconazole penetration into the central nervous system (CNS) is not known. A fluconazole PK study was conducted in 43 patients receiving oral fluconazole (usually 800 mg every 24 h [q24h]) in combination with amphotericin B deoxycholate (1 mg/kg q24h) for cryptococcal meningitis (CM). A four-compartment PK model was developed, and Monte Carlo simulations were performed for a range of fluconazole dosages. A meta-analysis of trials reporting outcomes of CM patients treated with fluconazole monotherapy was performed. Adjusted for bioavailability, the PK parameter means (standard deviation) were the following: clearance, 0.72 (0.24) liters/h; volume of the central compartment, 18.07 (6.31) liters; volume of the CNS compartment, 32.07 (17.60) liters; first-order rate constant from the central to peripheral compartment, 12.20 (11.17) h-1, from the peripheral to central compartment, 18.10 (8.25) h-1, from the central to CNS compartment, 35.43 (13.74) h-1, and from the CNS to central the compartment, 28.63 (10.03) h-1 Simulations of the area under concentration-time curve resulted in median (interquartile range) values of 1,143.2 (range, 988.4 to 1,378.0) mg · h/liter in plasma (AUCplasma) and 982.9 (range, 781.0 to 1,185.9) mg · h/liter in cerebrospinal fluid (AUCCSF) after a dosage of 1,200 mg q24h. The mean simulated ratio of AUCCSF/AUCplasma was 0.89 (standard deviation [SD], 0.44). The recommended dosage of fluconazole for CM induction therapy fails to attain the pharmacodynamic (PD) target in respect to the wild-type MIC distribution for C. neoformans The meta-analysis suggested modest improvements in both CSF sterility and mortality outcomes with escalating dosage. This study provides the pharmacodynamic rationale for the long-recognized fact that fluconazole monotherapy is an inadequate induction regimen for CM.
Subject(s)
Antifungal Agents/cerebrospinal fluid , Antifungal Agents/pharmacokinetics , Central Nervous System/metabolism , Fluconazole/cerebrospinal fluid , Fluconazole/pharmacokinetics , Meningitis, Cryptococcal/drug therapy , Adult , Aged , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Central Nervous System/microbiology , Cryptococcus neoformans/drug effects , Deoxycholic Acid/therapeutic use , Drug Combinations , Drug Therapy, Combination , Female , Fluconazole/therapeutic use , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Uganda , Vietnam , Young AdultABSTRACT
There is a limited understanding of the population pharmacokinetics (PK) and pharmacodynamics (PD) of amphotericin B deoxycholate (DAmB) for cryptococcal meningitis. A PK study was conducted in n = 42 patients receiving DAmB (1 mg/kg of body weight every 24 h [q24h]). A 2-compartment PK model was developed. Patient weight influenced clearance and volume in the final structural model. Monte Carlo simulations estimated drug exposure associated with various DAmB dosages. A search was conducted for trials reporting outcomes of treatment of cryptococcal meningitis patients with DAmB monotherapy, and a meta-analysis was performed. The PK parameter means (standard deviations) were as follows: clearance, 0.03 (0.01) × weight + 0.67 (0.01) liters/h; volume, 0.82 (0.80) × weight + 1.76 (1.29) liters; first-order rate constant from central compartment to peripheral compartment, 5.36 (6.67) h-1; first-order rate constant from peripheral compartment to central compartment, 9.92 (12.27) h-1 The meta-analysis suggested that the DAmB dosage explained most of the heterogeneity in cerebrospinal fluid (CSF) sterility outcomes but not in mortality outcomes. Simulations of values corresponding to the area under concentration-time curve from h 144 to h 168 (AUC144-168) resulted in median (interquartile range) values of 5.83 mg · h/liter (4.66 to 8.55), 10.16 mg · h/liter (8.07 to 14.55), and 14.51 mg · h/liter (11.48 to 20.42) with dosages of 0.4, 0.7, and 1.0 mg/kg q24h, respectively. DAmB PK is described adequately by a linear model that incorporates weight with clearance and volume. Interpatient PK variability is modest and unlikely to be responsible for variability in clinical outcomes. There is discordance between the impact that drug exposure has on CSF sterility and its impact on mortality outcomes, which may be due to cerebral pathology not reflected in CSF fungal burden, in addition to clinical variables.
Subject(s)
Amphotericin B/pharmacokinetics , Antifungal Agents/pharmacokinetics , Antifungal Agents/therapeutic use , Deoxycholic Acid/pharmacokinetics , Meningitis, Cryptococcal/drug therapy , Meningitis, Cryptococcal/metabolism , Adult , Aged , Amphotericin B/cerebrospinal fluid , Amphotericin B/therapeutic use , Antifungal Agents/cerebrospinal fluid , Deoxycholic Acid/cerebrospinal fluid , Deoxycholic Acid/therapeutic use , Drug Combinations , Female , Humans , Male , Meningitis, Cryptococcal/cerebrospinal fluid , Middle Aged , Monte Carlo Method , Prospective Studies , Young AdultABSTRACT
We report voriconazole levels in an infant with disseminated Candida glabrata infection who received combination antifungal therapy and rescue voriconazole treatment. Serum and cerebrospinal fluid voriconazole levels were higher than anticipated and above target. Dose reduction did not lead to a reduction in the blood or cerebrospinal fluid levels. The patient did not exhibit identifiable drug toxicity.
Subject(s)
Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Meningitis/drug therapy , Voriconazole/therapeutic use , Administration, Intravenous , Antifungal Agents/cerebrospinal fluid , Candida glabrata/drug effects , Candidiasis/cerebrospinal fluid , Drug Resistance, Fungal , Drug Therapy, Combination , Fatal Outcome , Humans , Infant , Infant, Premature , Male , Meningitis/microbiology , Microbial Sensitivity Tests , Multiple Organ Failure , Voriconazole/bloodABSTRACT
ABSTRACT Fluconazole is extensively used for the treatment of candidiasis and cryptococcosis. Among other factors, successful treatment is related to appropriate fluconazole levels in blood and cerebrospinal fluid. In the present study, fluconazole levels were determined in 15 patients, 14 of whom had AIDS and 13 had neurocryptococcosis. The only selection criterion was treatment with fluconazole, which was performed with a generic or similar form of the drug. Fluconazole level was determined by high performance liquid chromatography and the susceptibility profile of Cryptococcus spp. isolated from the patients was assessed by broth microdilution. Blood and cerebrospinal fluid fluconazole levels were found to be related to the fluconazole daily dose, and exceeded the minimum inhibitory concentration of this antifungal for the Cryptococcus spp. isolates. A good correlation was observed between serum and cerebrospinal fluid drug concentration. In conclusion, treatment with non-original fluconazole under usual medical practice conditions results in appropriate blood and cerebrospinal fluid levels of the drug for inhibiting Cryptococcus spp. susceptible to this antifungal drug. The relatively common failures of neurocryptococcosis treatment appear not to be due to insufficient fluconazole levels in the cerebrospinal fluid, especially with the use of daily doses of 400-800 mg.
Subject(s)
Humans , Adult , Middle Aged , Fluconazole/cerebrospinal fluid , Fluconazole/blood , Cryptococcosis/drug therapy , Antifungal Agents/cerebrospinal fluid , Antifungal Agents/blood , Reference Values , Candidiasis/cerebrospinal fluid , Candidiasis/drug therapy , Candidiasis/blood , Microbial Sensitivity Tests , Fluconazole/administration & dosage , Chromatography, High Pressure Liquid , Treatment Outcome , AIDS-Related Opportunistic Infections/drug therapy , Statistics, Nonparametric , Cryptococcosis/cerebrospinal fluid , Cryptococcosis/blood , Cryptococcus/isolation & purification , Cryptococcus/drug effects , Dose-Response Relationship, Drug , Histoplasmosis/cerebrospinal fluid , Histoplasmosis/drug therapy , Histoplasmosis/blood , Antifungal Agents/administration & dosageABSTRACT
The purpose of this study was to evaluate the influence of intracranial hypertension in the cerebrospinal fluid (CSF) levels of amphotericin B and fluconazole levels of patients with cryptococcal meningitis. CSF samples and intracranial pressure were obtained by means of routine punctures performed at days 1, 7, and 14 of therapy, respectively. Amphotericin B and fluconazole CSF levels were measured by HPLC method as previously described. The minimum inhibitory concentration for amphotericin B, fluconazole, 5Îflucytosine, and voriconazole of each Cryptococcus isolate was performed according to CLSI. The predominant Cryptococcus species found was C. neoformans, and the major underlying condition was AIDS. Only one CSF sample had a detectable level for amphotericin B during the 14 days of therapy. Fluconazole CSF levels progressively increased from day 1 to day 14 of therapy for most cases. Fluconazole levels in the CSF were above the minimum inhibitory concentrations (MICs) for Cryptococcus during the initial 14 days of antifungal therapy. Variations of intracranial pressure did not affect amphotericin B and fluconazole levels in the CSF. The generalized estimating correlation (GEE) and Spearman correlation test (SCT) showed no significant correlation between the amphotericin B or fluconazole concentrations in the CSF and intracranial pressure (P = .953 and P = .093, respectively for GEE test and P = .477 and P = .847, respectively, for SCT). Combination therapy of amphotericin B with fluconazole was effective in 60% of the patients considering CSF cultures were negative in 9 of 15 patients after 14 days of therapy. Further studies are necessary to evaluate the role of intracranial hypertension on the therapeutic efficacy of different antifungal agents in patients with cryptococcal meningitis.
Subject(s)
Amphotericin B/cerebrospinal fluid , Cryptococcus/drug effects , Fluconazole/cerebrospinal fluid , Intracranial Pressure/drug effects , Meningitis, Cryptococcal/drug therapy , Meningitis, Cryptococcal/physiopathology , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/microbiology , Adult , Aged , Amphotericin B/pharmacology , Amphotericin B/therapeutic use , Antifungal Agents/cerebrospinal fluid , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Brazil , Child , Cryptococcus/isolation & purification , Drug Therapy, Combination , Female , Fluconazole/pharmacology , Fluconazole/therapeutic use , Flucytosine/pharmacology , Follow-Up Studies , Humans , Male , Meningitis, Cryptococcal/cerebrospinal fluid , Meningitis, Cryptococcal/microbiology , Microbial Sensitivity Tests , Middle Aged , Tertiary Care Centers , Treatment Outcome , Voriconazole/pharmacologyABSTRACT
Fluconazole is extensively used for the treatment of candidiasis and cryptococcosis. Among other factors, successful treatment is related to appropriate fluconazole levels in blood and cerebrospinal fluid. In the present study, fluconazole levels were determined in 15 patients, 14 of whom had AIDS and 13 had neurocryptococcosis. The only selection criterion was treatment with fluconazole, which was performed with a generic or similar form of the drug. Fluconazole level was determined by high performance liquid chromatography and the susceptibility profile of Cryptococcus spp. isolated from the patients was assessed by broth microdilution. Blood and cerebrospinal fluid fluconazole levels were found to be related to the fluconazole daily dose, and exceeded the minimum inhibitory concentration of this antifungal for the Cryptococcus spp. isolates. A good correlation was observed between serum and cerebrospinal fluid drug concentration. In conclusion, treatment with non-original fluconazole under usual medical practice conditions results in appropriate blood and cerebrospinal fluid levels of the drug for inhibiting Cryptococcus spp. susceptible to this antifungal drug. The relatively common failures of neurocryptococcosis treatment appear not to be due to insufficient fluconazole levels in the cerebrospinal fluid, especially with the use of daily doses of 400-800mg.
Subject(s)
Antifungal Agents/blood , Antifungal Agents/cerebrospinal fluid , Cryptococcosis/drug therapy , Fluconazole/blood , Fluconazole/cerebrospinal fluid , AIDS-Related Opportunistic Infections/drug therapy , Adult , Antifungal Agents/administration & dosage , Candidiasis/blood , Candidiasis/cerebrospinal fluid , Candidiasis/drug therapy , Chromatography, High Pressure Liquid , Cryptococcosis/blood , Cryptococcosis/cerebrospinal fluid , Cryptococcus/drug effects , Cryptococcus/isolation & purification , Dose-Response Relationship, Drug , Fluconazole/administration & dosage , Histoplasmosis/blood , Histoplasmosis/cerebrospinal fluid , Histoplasmosis/drug therapy , Humans , Microbial Sensitivity Tests , Middle Aged , Reference Values , Statistics, Nonparametric , Treatment OutcomeABSTRACT
Amphotericin B (AMB), fluconazole (FZ), and fluorocytosine (FC) are recommended for HIV-associated cryptococcal meningitis (CM) patients as preferred antibiotics. This study presents a fast and automated online-dual-solid phase extraction (SPE)-LC coupled with high resolution mass spectrometer (HRMS) method to simultaneously measure the concentrations of AMB, FZ, and FC in human plasma and cerebrospinal fluid (CSF). Automated sample clean-up was performed on the human plasma and CSF samples with stop-flow heart-cutting two dimensional (2D) separation using a online-dual-SPE system, allowing retention and accumulation of AMB, FZ, and carbamazepine (CBZ, Internal standard (IS)) by the Oasis®HLB cartridge, and retention and accumulation of FC and 5-methylcytosine hydrochloride (MC, IS) by the HyperSep Hypercarb cartridge respectively. Followed by LC elution, quantification by Q-Exactive Hybrid Quadrupole-Orbitrap with targeted-selected ion monitoring (t-SIM) mode was applied to simultaneously determine the concentrations of AMB, FZ and FC. The bioanalysis was achieved in a total running time of 7min. The method was fully validated according to FDA guidelines. The lowest limit of quantification (LLOQ) was 0.04, 0.04, and 0.40µgmL-1 for AMB, FZ, and FC, respectively. AMB, FZ, and FC levels were linear in the ranges of 0.04-2.00µgmL-1, 0.04-2.00µgmL-1 and 0.40-20.00µgmL-1, respectively. The method showed good performance for human plasma and CSF samples with linearity (R2>0.99), intra-day and inter-day precision (relative standard deviation, RSD<4.32% and <4.06%, respectively), recovery (89.93-93.28% and 90.09-93.58%, respectively) and matrix effect (96.35-103.78% and 92.32-101.48%, respectively). The validated method was successfully applied in real samples of Chinese patients. Overall, our results indicate that this fully automated, sensitive, and reliable online-dual-SPE-LC-HRMS method is effective for therapeutic drug monitoring (TDM) of AMB, FZ, and FC levels.
Subject(s)
Amphotericin B/analysis , Chromatography, Liquid/methods , Drug Monitoring/methods , Fluconazole/analysis , Flucytosine/analysis , Solid Phase Extraction/methods , Tandem Mass Spectrometry/methods , Amphotericin B/blood , Amphotericin B/cerebrospinal fluid , Antifungal Agents/analysis , Antifungal Agents/blood , Antifungal Agents/cerebrospinal fluid , Fluconazole/blood , Fluconazole/cerebrospinal fluid , Flucytosine/blood , Flucytosine/cerebrospinal fluid , Humans , Online SystemsABSTRACT
This case report indicates the usefulness of voriconazole for the treatment of central nervous system (CNS) aspergillosis, also in paediatrics. However, it also confirms the need for therapeutic drug monitoring (TDM), especially in younger children that may require very high dosages in order to achieve plasma and cerebrospinal fluid (CSF) therapeutic concentrations.
Subject(s)
Antifungal Agents/administration & dosage , Neuroaspergillosis/drug therapy , Voriconazole/administration & dosage , Antifungal Agents/cerebrospinal fluid , Antineoplastic Agents/therapeutic use , Female , Humans , Immunocompromised Host , Infant , Neuroaspergillosis/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Voriconazole/cerebrospinal fluidABSTRACT
The goal of this project was to determine the pharmacokinetics of voriconazole and its concentration in cerebrospinal fluid (CSF), aqueous humor, and synovial fluid in five healthy dogs following once daily oral dose of 6 mg/kg for 2 weeks. Body fluid and plasma drug concentrations were determined by high-performance liquid chromatography (HPLC). Mild to moderate gastrointestinal adverse effects were seen. The mean AUC0-24 : minimum inhibitory concentration (MIC) ratio was 15.23 for a chosen MIC of 1 µg/mL, which is lower than the recommended target of 20-25 and also lower than previously reported in dogs, perhaps reflecting induction of metabolizing enzymes by multiple dosing. Voriconazole concentrations in the CSF, aqueous humor, and synovial fluid were only 13-30% the concurrent plasma concentration, which is lower than previously reported in other species. Results of this study suggest that twice daily, administration may be necessary to maintain therapeutic plasma concentrations in dogs but further studies are warranted.
Subject(s)
Antifungal Agents/pharmacokinetics , Voriconazole/pharmacokinetics , Administration, Oral , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/analysis , Antifungal Agents/blood , Antifungal Agents/cerebrospinal fluid , Aqueous Humor/chemistry , Chromatography, High Pressure Liquid/veterinary , Dogs , Female , Male , Microbial Sensitivity Tests/veterinary , Synovial Fluid/chemistry , Voriconazole/administration & dosage , Voriconazole/analysis , Voriconazole/blood , Voriconazole/cerebrospinal fluidABSTRACT
Superficial fungal infections of the hair, skin and nails are a major cause of morbidity in the world. Choosing the right treatment is not always simple because of the possibility of drug interactions and side effects. The first part of the article discusses the main treatments for superficial mycoses - keratophytoses, dermatophytosis, candidiasis, with a practical approach to the most commonly-used topical and systemic drugs , referring also to their dosage and duration of use. Promising new, antifungal therapeutic alternatives are also highlighted, as well as available options on the Brazilian and world markets.
As infecções fúngicas superficiais dos cabelos, pele e unhas representam uma causa importante de morbidade no mundo. O tratamento nem sempre é simples, havendo dificuldade na escolha dos esquemas terapêuticos disponíveis na literatura, assim como suas possíveis interações medicamentosas e efeitos colaterais. A segunda parte do trabalho aborda os principais esquemas terapêuticos das micoses superficiais - ceratofitoses, dermatofitoses, candidíase -, possibilitando a consulta prática das drogas tópicas e sistêmicas mais utilizadas, sua dosagem e tempo de utilização. Novas possibilidades terapêuticas antifúngicas também são ressaltadas, assim como as apresentações disponíveis no mercado brasileiro e mundial.
Subject(s)
Humans , Antifungal Agents/therapeutic use , Dermatomycoses/drug therapy , Antifungal Agents/cerebrospinal fluid , Drug Interactions , Time FactorsABSTRACT
Superficial fungal infections of the hair, skin and nails are a major cause of morbidity in the world. Choosing the right treatment is not always simple because of the possibility of drug interactions and side effects. The first part of the article discusses the main treatments for superficial mycoses - keratophytoses, dermatophytosis, candidiasis, with a practical approach to the most commonly-used topical and systemic drugs , referring also to their dosage and duration of use. Promising new, antifungal therapeutic alternatives are also highlighted, as well as available options on the Brazilian and world markets.
Subject(s)
Antifungal Agents/therapeutic use , Dermatomycoses/drug therapy , Antifungal Agents/cerebrospinal fluid , Drug Interactions , Humans , Time FactorsABSTRACT
We report a rare case of cryptococcal meningoencephalitis in which antifungal therapy was monitored by measuring the cerebrospinal fluid (CSF) levels of the antifungal drugs. A 78-year-old man with diabetes mellitus being treated with oral agents. He had no history of human immunodeficiency virus infection. The patient showed abnormal behavior and fever (>38°C) on November 20, 2009, and was admitted for disturbance of consciousness on November 24. CSF examination showed an increased cell count, and a yeast-like fungus, suggesting cryptococcal meningoencephalitis, was observed by India ink staining. Initial treatment was liposomal amphotericin B (L-AMB) plus flucytosine. Cryptococcus neoformans was isolated by CSF culture on day 2. MIC was 0.25 µg/ml for amphotericin B (AMPH-B), 4 µg/ml for flucytosine, 4 µg/ml for fluconazole (FLCZ), and 0.03 µg/ml for voriconazole (VRCZ). Despite treatment, his disturbance of consciousness persisted. The CSF level of AMPH-B was ≤0.05 µg/ml on day 8. Therefore, L-AMB was switched to fosfluconazole. The CSF level of FLCZ was sufficient (22.6 µg/ml) on day 25, but there was a decrease in glucose and the fungus could still be detected in CSF smears. Consequently, FLCZ was switched to VRCZ. On day 47, CSF level of VRCZ was 1.97 µg/ml, exceeding its MIC, so treatment was continued. On day 77, the patient was generally lucid, and CSF smears did not detect any fungi. The patient was then transferred for rehabilitation. On day 84, voriconazole was discontinued, with no evidence of fungal recurrence.
Subject(s)
Antifungal Agents/administration & dosage , Antifungal Agents/cerebrospinal fluid , Meningitis, Cryptococcal/cerebrospinal fluid , Meningitis, Cryptococcal/drug therapy , Meningoencephalitis/cerebrospinal fluid , Meningoencephalitis/drug therapy , Aged , Amphotericin B/administration & dosage , Amphotericin B/cerebrospinal fluid , Cryptococcus neoformans/drug effects , Fluconazole/administration & dosage , Fluconazole/analogs & derivatives , Fluconazole/cerebrospinal fluid , Humans , Male , Microbial Sensitivity Tests , Organophosphates/administration & dosage , Organophosphates/cerebrospinal fluid , Pyrimidines/administration & dosage , Pyrimidines/cerebrospinal fluid , Triazoles/administration & dosage , Triazoles/cerebrospinal fluid , VoriconazoleABSTRACT
The distribution of micafungin (MCFG) in tissue fluids, such as cerebrospinal fluid (CSF), pleural effusions, ascites, and wound tissue fluids, was examined in seven patients with invasive fungal infections. MCFG (100-300 mg) was administered once daily over a 1-h intravenous infusion. Blood and tissue fluid samples were collected from 1 to 24 h after infusion. Although two patients had similar MCFG concentrations in their plasma, the concentrations in the CSF differed between these two patients. The concentration in the CSF of one patient was much higher than the MIC(90) for Candida albicans, Candida glabrata, and Aspergillus fumigatus, whereas the MCFG concentration in the CSF of the other patient was comparable to the MIC(90). By contrast, MCFG concentrations in pleural effusions, ascites, and wound tissue fluids were above the MIC(90). These results suggest that intravenous MCFG may be effective to treat invasive fungal infections that invade the organs and tissues.
Subject(s)
Antifungal Agents/pharmacokinetics , Echinocandins/pharmacokinetics , Lipopeptides/pharmacokinetics , Mycoses/metabolism , Aged , Aged, 80 and over , Antifungal Agents/blood , Antifungal Agents/cerebrospinal fluid , Antifungal Agents/therapeutic use , Ascites/metabolism , Body Fluids/metabolism , Echinocandins/blood , Echinocandins/cerebrospinal fluid , Echinocandins/therapeutic use , Female , Humans , Lipopeptides/blood , Lipopeptides/cerebrospinal fluid , Lipopeptides/therapeutic use , Male , Micafungin , Middle Aged , Mycoses/drug therapy , Pleural Effusion/metabolism , Tissue DistributionABSTRACT
OBJECTIVES: The aim of the present study was to assess fluconazole pharmacokinetic measures in serum and cerebrospinal fluid (CSF); and the correlation of these measures with clinical outcomes of invasive fungal infections. METHODS: A randomized trial was conducted in HIV-infected patients receiving three different regimens of fluconazole plus amphotericin B (AmB) for the treatment of cryptococcal meningitis. Regimens included fluconazole 400 mg/day+AmB (AmB+Fluc400) or fluconazole 800 mg/day+AmB (AmB+Fluc800) (14 days followed by fluconazole alone at the randomized dose for 56 days); or AmB alone for 14 days followed by fluconazole 400 mg/day for 56 days. Serum (at 24 h after dosing) and CSF samples were taken at baseline and days 14 and 70 (serum only) for fluconazole measurement, using gas-liquid chromatography. RESULTS: Sixty-four treated patients had fluconazole measurements: 11 in the AmB group, 12 in the AmB+Fluc400 group and 41 in the AmB+Fluc800 group. Day 14 serum concentration geometric means were 24.7 mg/L for AmB+Fluc400 and 37.0 mg/L for AmB+Fluc800. Correspondingly, CSF concentration geometric means were 25.1 mg/L and 32.7 mg/L. Day 14 Serum and CSF concentrations were highly correlated with AmB+Fluc800 (P<0.001, r=0.873) and AmB+Fluc400 (P=0.005, r=0.943). Increased serum area under the curve (AUC) appears to be associated with decreased mortality at day 70 (P=0.061, odds ratio=2.19) as well as with increased study composite endpoint success at days 42 and 70 (P=0.081, odds ratio=2.25 and 0.058, 2.89, respectively). CONCLUSION: High fluconazole dosage (800 mg/day) for the treatment of HIV-associated cryptococcal meningitis was associated with high serum and CSF fluconazole concentration. Overall, high serum and CSF concentration appear to be associated with increased survival and primary composite endpoint success.
Subject(s)
Amphotericin B/pharmacokinetics , Antifungal Agents/pharmacokinetics , Fluconazole/pharmacokinetics , HIV Infections/metabolism , Meningitis, Cryptococcal/metabolism , Amphotericin B/blood , Amphotericin B/cerebrospinal fluid , Anti-HIV Agents/therapeutic use , Antifungal Agents/blood , Antifungal Agents/cerebrospinal fluid , Antiretroviral Therapy, Highly Active , Biological Availability , Chromatography, Gas , Dose-Response Relationship, Drug , Drug Therapy, Combination , Fluconazole/blood , Fluconazole/cerebrospinal fluid , HIV Infections/complications , HIV Infections/drug therapy , Humans , Meningitis, Cryptococcal/drug therapy , Meningitis, Cryptococcal/mortality , Models, Biological , Risk Factors , Time Factors , Treatment OutcomeABSTRACT
Coccidioidal meningitis is a lethal disease, and current therapy is not curative or is burdened with serious toxicities and logistic difficulties. In a patient with refractory disease, continuous infusion amphotericin B therapy was given via a programmable implanted pump into the cisternal subarachnoid space. The patient progressively responded, evidenced clinically and by laboratory studies. Drug delivery issues were addressed during this course that could guide future use of this modality, which is a promising novel avenue of therapy for chronic meningitis.
Subject(s)
Amphotericin B , Antifungal Agents , Infusion Pumps, Implantable , Amphotericin B/administration & dosage , Amphotericin B/cerebrospinal fluid , Amphotericin B/therapeutic use , Antifungal Agents/administration & dosage , Antifungal Agents/cerebrospinal fluid , Antifungal Agents/therapeutic use , Coccidioidomycosis/cerebrospinal fluid , Coccidioidomycosis/drug therapy , Humans , Injections, Spinal , Male , Meningitis, Fungal/cerebrospinal fluid , Meningitis, Fungal/drug therapy , Young AdultABSTRACT
Cerebral aspergillosis is increasingly recognized in severely immunocompromised patients and, until recently, this type of fungal infection was associated with a mortality approaching 100%. The central nervous system is a protected environment and penetration of drugs across the blood-brain barrier is mainly limited by their molecular size and physicochemical properties, as well as drug interaction with transporter systems (e.g., P-glycoprotein) at the blood-brain barrier. Most antifungal agents are large molecules (>700 Da), which makes sufficient penetration into the central nervous system unlikely. In fact, the available data indicate low levels of most antifungal agents in cerebrospinal fluid and brain tissue, except for fluconazole and voriconazole. Concentrations of voriconazole exceeding inhibitory concentrations for Aspergillus species were found repeatedly in cerebrospinal fluid and brain tissue, including brain abscess material. A recent retrospective study confirmed that voriconazole treatment resulted in improved response and survival rates in patients with cerebral aspergillosis. Data from animal models, which explored escalated doses or combinations of antifungal agents in experimental neuroaspergillosis, suggest that selected combination or dose-escalated therapies might further improve the still unsatisfactory prognosis in this particular type of Aspergillus infection.
Subject(s)
Antifungal Agents/pharmacokinetics , Fluconazole/pharmacokinetics , Neuroaspergillosis/drug therapy , Pyrimidines/pharmacokinetics , Triazoles/pharmacokinetics , Animals , Antifungal Agents/cerebrospinal fluid , Antifungal Agents/therapeutic use , Fluconazole/cerebrospinal fluid , Fluconazole/therapeutic use , Humans , Pyrimidines/cerebrospinal fluid , Pyrimidines/therapeutic use , Triazoles/cerebrospinal fluid , Triazoles/therapeutic use , VoriconazoleSubject(s)
Antifungal Agents/cerebrospinal fluid , Aspergillosis/cerebrospinal fluid , Aspergillosis/drug therapy , Hematopoietic Stem Cell Transplantation/methods , Lung Diseases, Fungal/cerebrospinal fluid , Lung Diseases, Fungal/drug therapy , Triazoles/cerebrospinal fluid , Acute Disease , Antifungal Agents/administration & dosage , Antifungal Agents/pharmacokinetics , Central Nervous System Fungal Infections/cerebrospinal fluid , Central Nervous System Fungal Infections/drug therapy , Humans , Leukemia, Myeloid/therapy , Male , Triazoles/administration & dosage , Triazoles/pharmacokinetics , Young AdultABSTRACT
The goal in treatment of infections is to achieve a beneficial effect while minimizing toxicity. It is widely recognized that the principles of pharmacokinetics and pharmacodynamics are critical to determining an adequate dose-response relationship. There has been an increased involvement of the CNS to infection from opportunistic and endemic fungi over the last several decades due to establishment of solid-organ and bone marrow transplantation as well as immunosuppression from HIV. In this regard it has become critical to define optimal dosing regimens by an understanding of the processes which govern delivery of an antifungal agent to the targeted CNS site of involvement. The objective of this review is to: i) summarize published experimental and clinical antifungal pharmacokinetics; and ii) examine the relationship between CNS antifungal pharmacokinetics and efficacy. Examination of these studies reveal marked variability among antifungal drugs with regard to cerebrospinal fluid and brain parenchymal penetration. Formal examination of the relationship between CNS antifungal pharmacokinetics and efficacy are limited. The few experimental studies available suggest that brain parenchymal kinetics is a superior predictor of antifungal efficacy than cerebrospinal fluid concentrations.